Maria Elena Dela Rosa, NP
Family · Duarte, CANPI 1013449206
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $36,600 of the $55,276 with a category attached, or 66.2%. 34 manufacturers reported payments, led by Pharmacyclics LLC, An Abbvie Company at 42.1% of the total. Reporting peaked in 2023 at $26,820 and has fallen 73.2% since, to $7,195 in 2025. Among family clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 350 payments — averaging $157.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pharmacyclics LLC, An Abbvie Company$23K
- AstraZeneca$13K
- AbbVie$9K
- Johnson & Johnson$3K
- Janssen Scientific Affairs, LLC$600
- Beigene USA, Inc.$563
- plus $5K from 28 others
What the payments were for
- Consulting fees$1,8753%
- Speaking & faculty fees$36,60066%
- Travel & lodging$4,2218%
- Food & beverage$11,81921%
- Education$7611%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | 46 | $23,244 |
| AstraZeneca(2 entities) | 75 | $13,463 |
| AbbVie | 40 | $9,490 |
| Johnson & Johnson(2 entities) | 39 | $3,279 |
| Janssen Scientific Affairs, LLC | 1 | $600 |
| Beigene USA, Inc. | 19 | $563 |
| Incyte Corporation | 9 | $522 |
| Beone Medicines USA, Inc. | 12 | $391 |
| Seagen Inc. | 7 | $378 |
| Astellas Pharma US Inc | 7 | $293 |
| Bristol Myers Squibb | 11 | $284 |
| Secura Bio, Inc. | 5 | $271 |
| Jazz Pharmaceuticals Inc. | 6 | $239 |
| Genentech USA, Inc. | 8 | $211 |
| Merck | 7 | $204 |
| Daiichi Sankyo Inc. | 9 | $183 |
| Novartis | 7 | $177 |
| Sanofi | 6 | $174 |
| EMD Serono, Inc. | 4 | $158 |
| Syndax Pharmaceuticals, Inc. | 1 | $130 |
| Lilly USA, LLC | 2 | $125 |
| Epizyme, Inc. | 1 | $125 |
| E.r. Squibb & Sons, L.L.C. | 1 | $117 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $107 |
| Genmab U.S., Inc. | 2 | $107 |
| Sobi, Inc | 3 | $80 |
| Amgen | 5 | $75 |
| Helsinn Therapeutics (U.S.), Inc. | 4 | $63 |
| Gilead | 2 | $50 |
| Regeneron Healthcare Solutions, Inc. | 2 | $41 |
| Rigel Pharmaceuticals, Inc. | 2 | $41 |
| Pharmaessentia USA Corporation | 1 | $33 |
| Karyopharm Therapeutics Inc. | 1 | $32 |
| ADC Therapeutics America, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$55,276 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 78 | $1,107,564 |
| BrukinsaZanubrutinib | 53 | $571,880 |
| VenclextaVenetoclax | 24 | $225,809 |
| ImbruvicaIbrutinib | 11 | $160,741 |
| EliquisApixaban | 15 | $9,870 |
| Enoxaparin Sodium | 13 | $2,231 |
| Acyclovir | 132 | $1,743 |
| ValacyclovirValacyclovir Hcl | 36 | $1,592 |
| Potassium Chloride | 28 | $639 |
| Famotidine | 13 | $224 |
| Pantoprazole Sodium | 25 | $200 |
| Prednisone | 15 | $185 |
| Allopurinol | 36 | $139 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 25 | $89 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $58 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $13,463 | $1,107,56478 claims |
| Beigene USA, Inc.Brukinsa | $563 | $571,88053 claims |
| AbbVieVenclexta | $9,490 | $225,80924 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $23,244 | $160,74111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.
Other family in Duarte
- Marjorie HeinDuarte$50K
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Erin DwyerSan Diego$189K
- Phyllis CasonLos Angeles$187K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.